Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Venn diagrams of the number of DEGs between each comparison. by Wardah K. Mustahsan (17484456)

Surgery design. by Maria Nadinskaia (22662419)

Variation law of AE events rate of sandstone under different freeze-thaw cycles at a loading rate of 0.05 mm/min. by Wenyu Lv (20139458)

Variation law of AE events rate of sandstone under different freeze-thaw cycles at a loading rate of 0.05 mm/min. by Wenyu Lv (20139458)

Morphometric analysis of histological slides in sarcopenia modeling by portal vein ligation and pyloric vein ligation. by Maria Nadinskaia (22662419)

DataSheet1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”

DataSheet3_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”

DataSheet2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”

DataSheet4_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”

Supporting information – data for plots. by Maria Nadinskaia (22662419)

Sequential viral infection is associated with reduced antibody response to intramuscular and intranasal ChAd-SARS-CoV-2 vaccination. by Yuhao Li (1559569)

Predicted confidence scores and 95% confidence intervals for the range of observed knowledge scores for barrier scores of 12, 23 and 36. by Lisa Thiele (6468056)

Data Sheet 1_The gastric microbiome altered by A4GNT deficiency in mice.zip by Dawei Gong (3070773)

“…Background<p>Selective antimicrobial effects have been found for α1,4-linked N-acetylglucosamine residues at the terminus of O-glycans attached to a core protein of gastric gland mucin. A4gnt encodes α1,4-N-acetylglucosaminyl transferase, which is responsible for the biosynthesis of α1,4-linked N-acetylglucosamine. …”

The CYP7B1 inhibitor, clotrimazole, and the EBI2 receptor antagonist, NIBR189, attenuate LPS-induced astrocyte migration <i>in vitro.</i> by Fionä Caratis (12759506)

Effect of <i>T. oliverianum</i> extracts on liver enzymes and total bilirubin. by Rania F. Ahmed (10032039)

Effects of <i>T. oliverianum</i> extracts on hepatic content of GSH and MDA. by Rania F. Ahmed (10032039)

Effect of <i>T. olivarium</i> extracts on hepatic content of TNF-<i>α.</i> by Rania F. Ahmed (10032039)

Tight junction and adhesion proteins in the brain are downregulated during systemic inflammation. by Fionä Caratis (12759506)

“…<p>A. The mRNA levels of <i>Occludin</i> were significantly reduced after 12 hours post LPS injection (12 h: 57% + /- 12% vs. vehicle) and started to return to the vehicle levels after 24 hours. …”